Selected article for: "general population and risk factor"
Author: Orioli, Laura; Hermans, Michel P; Thissen, Jean-Paul; Maiter, Dominique; Vandeleene, Bernard; Yombi, Jean-Cyr
Title: COVID-19 in diabetic patients: related risks and specifics of management
  • Cord-id: 0tsefy6p
  • Document date: 2020_5_12
    • ID: 0tsefy6p
    Snippet: Abstract Diabetes is among the most frequently reported comorbidities in patients infected with COVID-19. According to current data, diabetic patients do not appear to be at increased risk of contracting SARS-CoV-2 compared to the general population. On the other hand, diabetes is a risk factor for developing severe and critical forms of COVID-19, the latter requiring admission to an intensive care unit and/or use of invasive mechanical ventilation, with high mortality rates. The characteristics
    Document: Abstract Diabetes is among the most frequently reported comorbidities in patients infected with COVID-19. According to current data, diabetic patients do not appear to be at increased risk of contracting SARS-CoV-2 compared to the general population. On the other hand, diabetes is a risk factor for developing severe and critical forms of COVID-19, the latter requiring admission to an intensive care unit and/or use of invasive mechanical ventilation, with high mortality rates. The characteristics of diabetic patients at risk for developing severe and critical forms of COVID-19, as well as the prognostic impact of diabetes on the course of COVID-19, are under current investigation. Obesity, the main risk factor for incident type 2 diabetes, is more common in patients with critical forms of COVID-19 requiring invasive mechanical ventilation. On the other hand, COVID-19 is usually associated with poor glycemic control and a higher risk of ketoacidosis in diabetic patients. There are currently no recommendations in favor of discontinuing antihypertensive medications that interact with the renin-angiotensin-aldosterone system. Metformin and SGLT2 inhibitors should be discontinued in patients with severe forms of COVID-19 owing to the risks of lactic acidosis and ketoacidosis. Finally, we advise for systematic screening for (pre)diabetes in patients with proven COVID-19 infection.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acei ace inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ace inhibitor and acute cardiac injury: 1, 2
    • ace inhibitor and acute infection: 1, 2, 3, 4, 5
    • ace inhibitor and acute kidney injury: 1, 2, 3, 4
    • ace inhibitor and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • ace inhibitor and acute respiratory distress syndrome ards: 1, 2, 3, 4
    • ace inhibitor and admission prior: 1
    • acei ace inhibitor and acute infection: 1
    • acei ace inhibitor and acute respiratory: 1, 2, 3
    • acute cardiac injury and admission prior: 1
    • acute infection and admission hba1c: 1, 2
    • acute infection and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute kidney injury and admission hba1c: 1
    • acute kidney injury and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory and admission hba1c: 1, 2, 3, 4, 5, 6
    • acute respiratory and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and admission hba1c: 1
    • acute respiratory distress syndrome and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14